Ligand validation:6WNP

U5G: boceprevir (bound form)

U5G is a Ligand Of Interest in 6WNP designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6WNP_U5G_A_401	70%	4%	0.097	0.915	4.1	1.72	10	10	0	0	100%	1
7K40_U5G_A_401	92%	18%	0.065	0.957	2.11	1.46	13	11	0	0	100%	0.973
6XQU_U5G_A_401	82%	80%	0.106	0.962	0.28	0.56	-	1	0	0	100%	1
7NBR_U5G_AAA_401	78%	14%	0.129	0.972	1.18	2.68	3	13	0	0	100%	1
6ZRU_U5G_A_503	77%	51%	0.112	0.953	1.11	0.79	2	-	0	0	100%	1
7BRP_U5G_A_401	73%	4%	0.108	0.935	3.02	2.64	21	15	0	0	100%	1
7C6S_U5G_A_401	72%	55%	0.096	0.918	1.1	0.65	1	-	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.